Oragen Therapeutics is a clinical-stage biotech developing RNA-based therapies for inflammatory bowel disease (IBD), with a lead program targeting oral delivery of mRNA to inflamed intestinal tissue. The company’s proprietary formulation platform addresses the need for durable remission and mucosal healing in conditions like Crohn’s disease and ulcerative colitis, moving beyond systemic immunosuppression toward locally acting, targeted treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for inflammatory bowel disease (IBD), including biologics and small molecules, often require systemic administration, carry significant side effects, and lose effectiveness over time. Many patients fail to achieve durable remission or mucosal healing, leaving a substantial unmet need for therapies that act locally in the gut while minimizing systemic exposure and resistance.
Solution
Oragen Therapeutics is developing a novel oral RNA therapy platform designed to deliver therapeutic mRNA directly to inflamed intestinal tissue. This approach enables local production of anti-inflammatory proteins at the disease site, potentially achieving high efficacy with reduced systemic toxicity. The company’s lead candidate targets key inflammatory pathways in IBD, with the goal of inducing and maintaining remission in Crohn’s disease and ulcerative colitis. Preclinical data suggest the platform achieves efficient intestinal uptake and prolonged protein expression, positioning it as a durable and convenient alternative to injectable biologics.
Target Audience
The primary audience includes gastroenterologists and IBD specialists, as well as patients with moderate-to-severe Crohn’s disease or ulcerative colitis who have failed or are intolerant to existing biologic therapies.
Features
- Orally administered mRNA formulation engineered for targeted delivery to inflamed gut mucosa
- Proprietary lipid nanoparticle technology optimized for gastrointestinal stability and cellular uptake
- Designed to induce local expression of therapeutic proteins, reducing systemic immunosuppression
- Preclinical candidate validated for efficacy and tolerability in IBD models
- Platform scalable to multiple inflammatory and gastrointestinal indications beyond IBD